It indicates that WMJ-J-09 not only functions as an effective HDAC inhibitor but may also have advantages over existing pan-HDAC inhibitors in targeting p53-deficient or chemoresistant CRC cells. This evidence concerns the gene TP53 and colorectal carcinoma.